Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
15 hedge funds and large institutions have $74.5K invested in Baudax Bio, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
25% more funds holding
Funds holding: 12 → 15 (+3)
51% less capital invested
Capital invested by funds: $152K → $74.5K (-$77.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$25.9K |
| 2 |
VF
Virtu Financial
New York
|
+$23.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$13.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$52.7K |
| 2 |
Jane Street
New York
|
-$32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.6K |
BXRX Hedge Fund Activity: Q3 2023 in Review
15 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2023, worth a combined $74.5K — down 51% from $152K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BXRX positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $25.9K. The largest seller was Creative Planning, exiting entirely with an estimated $52.7K sold.
- 15 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2023, up from 12 in Q2 2023.
- Funds reported $74.5K of Baudax Bio, Inc. Common Stock stock for Q3 2023, down 51% quarter-over-quarter.
- 5 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of +3 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $25.9K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q3 2023 was Creative Planning, an estimated $52.7K sold.
Based on aggregated 13F filings for Q3 2023.